Predicting Biologic Therapy Success in Ulcerative Colitis
Part of Digestive system clinical trials.
This study uses an intestinal ultrasound and fat measurements to see if they can predict how well biologic therapies will work for people with active ulcerative colitis. The goal is to find better ways to choose treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have active ulcerative colitis with symptoms like rectal bleeding, frequent stools, or mucus.
- You are not pregnant.
- You have not had your colon removed (colectomy).
- You agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
This study tests whether an ultrasound score (called VAT) combined with another ultrasound score (IUS) can predict how well anti-TNF medications (like infliximab) work for people with inflammatory bowel disease. If you are starting a new anti-TNF treatment, this study may help doctors understand if the medication will be effective for you.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
This study uses intestinal ultrasound to see if vedolizumab can heal the gut in people recently diagnosed with Crohn's disease. It aims to find early signs that the treatment is working.
Hear when a new Predicting Biologics Success Via VAT Assessment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.